Teva Pharmaceutical Industries Limited

Cornelia Mascio
Agosto 16, 2017

Puplava Financial Services Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Teva Pharmaceutical Industries Limited has a 1-year low of $16.81 and a 1-year high of $54.83.

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Salem Investment Counselors boosted its stake in Teva Pharmaceutical Industries by 0.4% in the Q1. Salem Investment Counselors Inc. now owns 8,332 shares of the company's stock worth $267,000 after buying an additional 32 shares during the period.

Copper Rock Capital Partners Llc holds 2.76% of its portfolio in NutriSystem Inc. for 1.24 million shares. Northern Cross LLC raised its position in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Chevy Chase Trust Holdings Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.4% in the first quarter.

TRADEMARK VIOLATION NOTICE: "Teva Pharmaceutical Industries Limited (NYSE:TEVA) Upgraded to "Strong-Buy" by Vetr Inc." was first published by The Cerbat Gem and is owned by of The Cerbat Gem. Greylin Investment Mangement Inc. now owns 294,495 shares of the company's stock valued at $9,783,000 after buying an additional 79,300 shares during the last quarter.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a large growth in short interest in the month of June. The firm's 50-day moving average is $28.78 and its 200 day moving average is $31.30. The stock has a market cap of $17.78 billion, a P/E ratio of 224.36 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. During the same period in the prior year, the company earned $1.25 EPS. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is presently -18.95%. The company reported revenue of $6.39 Billion in the same period a year ago. The business's revenue for the quarter was up 12.9% on a year-over-year basis.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th.

Based on the stock's volatility for the week, which is a statistical measure of the dispersion of returns for a given stock and represents average daily high/low percentage range of 2.96% and month of 1.78%. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States & worldwide copyright law. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/16/river-wealth-advisors-llc-reduces-stake-in-teva-pharmaceutical-industries-limited-nyseteva-updated.html. Citigroup maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, July 28 with "Buy" rating. Goldman Sachs maintained the stock with "Buy" rating in Monday, August 10 report.

August 7 investment analysts at Barclays left the stock rating at "Equal-Weight" but moved down the price target to $23.00 from $46.00. Cantor Fitzgerald maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Thursday, June 22 with "Hold" rating. Comparatively, Teva Pharmaceutical Industries Limited posted earnings of $1.51 per share in the same quarter a year ago. Three investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Hold" rating given on Thursday, July 13 by Maxim Group. Teva Pharmaceutical Industries Limited (TEVA) received interesting focus from Active Investors and it has been trading on front line as comparing to it past average volume.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE